Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern

View ORCID ProfileMatheus Filgueira Bezerra, Lais Ceschini Machado, Viviane do Carmo Vasconcelos de Carvalho, Cássia Docena, Sinval Pinto Brandão-Filho, Constância Flávia Junqueira Ayres, Marcelo Henrique Santos Paiva, Gabriel Luz Wallau
doi: https://doi.org/10.1101/2021.03.20.21253956
Matheus Filgueira Bezerra
1Departamento de Microbiologia – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matheus Filgueira Bezerra
Lais Ceschini Machado
2Departamento de Entomologia e Núcleo de Bioinformática – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane do Carmo Vasconcelos de Carvalho
3Núcleo de Plataforma Técnológica – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cássia Docena
3Núcleo de Plataforma Técnológica – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sinval Pinto Brandão-Filho
4Departamento de Parasitologia, Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constância Flávia Junqueira Ayres
2Departamento de Entomologia e Núcleo de Bioinformática – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcelo Henrique Santos Paiva
2Departamento de Entomologia e Núcleo de Bioinformática – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
5Centro Acadêmico do Agreste, Núcleo de Ciências da Vida. Universidade Federal de Pernambuco, Caruaru, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marcelo.paiva@fiocruz.br gabriel.wallau@fiocruz.br
Gabriel Luz Wallau
2Departamento de Entomologia e Núcleo de Bioinformática – Instituto Aggeu Magalhães; Fiocruz. Recife, PE, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marcelo.paiva@fiocruz.br gabriel.wallau@fiocruz.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The global spread of new SARS-CoV-2 variants of concern underscore an urgent need of simple deployed molecular tools that can differentiate these lineages. Several tools and protocols have been shared since the beginning of the COVID-19 pandemic, but they need to be timely adapted to cope with SARS-CoV-2 evolution. Although whole-genome sequencing (WGS) of the virus genetic material have been widely used, it still presents practical difficulties such as high cost, shortage of available reagents in the global market, need of a specialized laboratorial infrastructure and well-trained staff. These limitations result in genomic surveillance blackouts across several countries. Here we propose a rapid and accessible protocol based on Sanger sequencing of a single PCR fragment that is able to identify and discriminate all SARS-CoV-2 variants of concern (VOCs) identified so far, according to each characteristic mutational profile at the Spike-RBD region (K417N/T, E484K, N501Y, A570D). Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three from P.2, two from P.1 and seven from B.1.1 lineage. All results from the Sanger sequencing method perfectly matched the mutational profile of VOCs and non-VOCs described by WGS. In summary, this approach allows a much broader network of laboratories to perform molecular surveillance of SARS-CoV-2 VOCs and report results within a shorter time frame, which is of utmost importance in the context of rapid public health decisions in a fast evolving worldwide pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Gabriel Luz Wallau was supported by the National Council for Scientific and Technological Development by the productivity research fellowship level 2 (303902/2019-1).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Aggeu Magalhaes Institute's Ethical Commitee (Fiocruz-IAM), protocol number CAAE32333120.4.0000.5190.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All genomes generated in this study are deposited on GISAID under the accessions: EPI_ISL_500460, EPI_ISL_500461, EPI_ISL_500865, EPI_ISL_500868, EPI_ISL_500872, EPI_ISL_500477, EPI_ISL_500482, EPI_ISL_1239012, EPI_ISL_1239013, EPI_ISL_1239014, EPI_ISL_1239015, EPI_ISL_1239016

https://www.gisaid.org

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern
Matheus Filgueira Bezerra, Lais Ceschini Machado, Viviane do Carmo Vasconcelos de Carvalho, Cássia Docena, Sinval Pinto Brandão-Filho, Constância Flávia Junqueira Ayres, Marcelo Henrique Santos Paiva, Gabriel Luz Wallau
medRxiv 2021.03.20.21253956; doi: https://doi.org/10.1101/2021.03.20.21253956
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern
Matheus Filgueira Bezerra, Lais Ceschini Machado, Viviane do Carmo Vasconcelos de Carvalho, Cássia Docena, Sinval Pinto Brandão-Filho, Constância Flávia Junqueira Ayres, Marcelo Henrique Santos Paiva, Gabriel Luz Wallau
medRxiv 2021.03.20.21253956; doi: https://doi.org/10.1101/2021.03.20.21253956

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11639)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4654)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)